Michael has 25 years of experience in the CRO Industry. Prior to joining Novotech in 2017, Michael spent 15 years building and leading operations across Asia for Quintiles/IQVIA, and was senior advisor for TPG Capital.

Zidong Zhang is responsible for all aspects of financial management to support the growth of Novotech across Asia. Prior to joining Novotech, Dr. Zhang was CFO at Shanghai Henlius Biotech, Inc. a Hong Kong-listed global biopharmaceutical company based in Shanghai, where he built and managed the finance team and played an integral role in the company’s initial public offering in 2019. Prior to that, Dr. Zhang was an equity research analyst at UBS in New York, where he covered the United States large cap pharmaceutical and specialty pharmaceutical sector.

Andy worked at Covance, Inc., a global CRO, for more than 10 years in a number of executive positions. Most recently, he was General Manager of Covance's Central Laboratory Service, Asia Pacific, where he led a large multi-functional team of across multiple sites in APAC. Andy holds an MBA from the University of Chicago, an MS in Electrical Engineering from the Rose-Hulman Institute of Technology, and a BS in Electrical Engineering from Tsinghua University.

Veronica는 2014년 5월 노보텍에 입사하여 노보텍의 법률 부서를 구축했습니다. 노보텍에 합류하기 전, Veronica는 EY에서 선임 변호사, Clayton Utz에서 선임 사무 변호사 및 Novartis Pharmaceuticals Australia Pty Limited에서 법무 자문위원(파견직)으로 활동했습니다. Veronica는 BA/LLB/LLM을 취득했습니다.